Company: CNTB
Filing Date: 2025-06-10
Form Type: F-3
Source: 0001193125-25-138482
Chunk: 2

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-06-10
Form: F-3
Chunk 2
---
 amounts, prices and terms of the securities. The prospectus supplement may also add, update or change information
contained in this prospectus with respect to that offering. You should carefully read this prospectus and any applicable prospectus supplement before you invest in any of our securities.

We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more
underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price, fee,
commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus entitled “About this Prospectus”
and “Plan of Distribution” for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities.

As of June 9, 2025, the aggregate market value of our outstanding American Depositary Shares held by non-affiliates, or public float, was approximately $35,102,960.85, based on 55,561,056 American Depositary Shares, of which 14,263,455 shares were held by affiliates, and a price of $0.85 per share, which was the
price at which our American Depositary Shares were last sold on the Nasdaq Global Market on May 20, 2025. We have not sold any securities pursuant to General Instruction I.B.5 of Form F-3 during the prior
12-calendar-month period that ends on and includes the date of this prospectus. Pursuant to General Instruction I.B.5 of Form F-3, in no event will we sell securities
registered on this registration statement in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as
our public float remains below $75 million.

INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE “ RISK FACTORS” ON PAGE 15 OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT OR IN THE DOCUMENTS INCORPORATED BY REFERENCE INTO THIS PROSPECTUS CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN